Inhibition of plasma kallikrein prevents peptidoglycan‐induced arthritis in the Lewis rat

We investigate whether the previously shown contact system activation plays a pathogenetic role in a rat model of acute inflammation induced by peptidoglycan‐polysaccharide (PG‐APS) using a new specific plasma kallikrein inhibitor, Bz‐Pro‐Phe‐boroArg‐OH (P8720). Group I (control) received neither PG‐APS nor inhibitor. Group II (disease‐treated) received PG‐APS intraperitoneally (IP) and P8720 orally. Group III (disease‐untreated) received PG‐APS IP. Anemia was evident at 49 h in group III but was not present (P < 0.01) in groups I and II. Spleen weight was significantly decreased in group II compared to group III. Acute arthritis progressively developed in group III from 27 to 49 h, but P8720 decreased the joint swelling in group II by 61% (P < 0.0005). We observed a significant fall in prekallikrein and factor XI (P < 0.01) in groups II and III but not in group I. The decrease in the functional levels of high molecular weight kininogen (P < 0.05) observed in group III were prevented by P8720 in group II. The changes in T‐kininogen and α1‐inhibitor 3 acute‐phase proteins were partially prevented by P8720. We conclude that the inflammatory reactions leading to arthritis and anemia, as well as the acute‐phase reaction, are due in part to contact activation, and that specific kallikrein inhibitors may have therapeutic potential.—DeLa Cadena, R. A., Stadnicki, A., Uknis, A. B., Sartor, R. B., Kettner, C. A., Adam, A., Colman, R. W. Inhibition of plasma kallikrein prevents peptidoglycan‐induced arthritis in the Lewis rat. FASEB J. 9, 446–452 (1995)

[1]  J. Schwab,et al.  Phlogistic properties of peptidoglycan-polysaccharide polymers from cell walls of pathogenic and normal-flora bacteria which colonize humans , 1993, Infection and immunity.

[2]  R. Colman,et al.  Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. , 1993, Blood.

[3]  Z. Toossi,et al.  Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Timmermans,et al.  In Vivo Characterization of a New Synthetic Thrombin Inhibitor , 1992, Thrombosis and Haemostasis.

[5]  R. Thompson,et al.  Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats , 1991, Infection and Immunity.

[6]  R. Tidwell,et al.  Streptococcal cell wall-induced systemic disease. Beneficial effects of trans-bis(5-amidino-2-benzimidazolyl)ethene, a novel, macrophage-directed anti-inflammatory agent. , 1991, The American journal of pathology.

[7]  R. Colman,et al.  Localization of distinct functional domains on prekallikrein for interaction with both high molecular weight kininogen and activated factor XII in a 28-kDa fragment (amino acids 141-371). , 1991, The Journal of biological chemistry.

[8]  R. Fisher,et al.  Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation. , 1991, American Journal of Physiology.

[9]  R. Knabb,et al.  The selective inhibition of thrombin by peptides of boroarginine. , 1990, The Journal of biological chemistry.

[10]  A. Adam,et al.  Quantification of rat T-kininogen using immunological methods. Application to inflammatory processes. , 1989, Biochemical pharmacology.

[11]  W. J. Cromartie,et al.  Protracted anemia associated with chronic, relapsing systemic inflammation induced by arthropathic peptidoglycan-polysaccharide polymers in rats , 1989, Infection and immunity.

[12]  R. Brown,et al.  Mast cell activation by group A streptococcal polysaccharide in the rat and its role in experimental arthritis. , 1988, The American journal of pathology.

[13]  R. Colman,et al.  A simple and accurate microplate assay for the determination of factor XI in plasma. , 1988, The Journal of laboratory and clinical medicine.

[14]  A. Schmaier,et al.  Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. , 1988, The Journal of laboratory and clinical medicine.

[15]  R. Colman,et al.  RECOMBINANT ALPHA-1-ANTITRYPSIN PITTSBURGH ATTENUATES EXPERIMENTAL GRAM-NEGATIVE SEPTICEMIA , 1988, Thrombosis and Haemostasis.

[16]  R. Colman,et al.  Evaluation of a microassay for human plasma prekallikrein. , 1987, The Journal of laboratory and clinical medicine.

[17]  C. Kettner,et al.  Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids. , 1984, The Journal of biological chemistry.

[18]  R. Colman,et al.  Human plasma kallikrein releases neutrophil elastase during blood coagulation. , 1983, The Journal of clinical investigation.

[19]  N. Back,et al.  Rodent kinin-forming enzyme systems--I. Purification and characterization of plasma kininogen. , 1983, Biochemical pharmacology.

[20]  R. Brown,et al.  Edema-producing activity of group A streptococcal polysaccharide and its possible role in the pathogenesis of cell wall-induced polyarthritis , 1983, The Journal of experimental medicine.

[21]  R. Colman,et al.  Purified human plasma kallikrein aggregates human blood neutrophils. , 1982, The Journal of clinical investigation.

[22]  R. H. Walmsley,et al.  Manual of pharmacologic calculations with computer programs , 1982 .

[23]  W. J. Cromartie,et al.  Arthropathic Properties Related to the Molecular Weight of Peptidoglycan-Polysaccharide Polymers of Streptococcal Cell Walls , 1982, Infection and immunity.

[24]  John D Lambris,et al.  In vivo changes in complement induced with peptidoglycan-polysaccharide polymers from streptococcal cell walls , 1982, Infection and immunity.

[25]  E. Shaw,et al.  Active site mapping of human and rat urinary kallikreins by peptidyl chloromethyl ketones. , 1980, Archives of biochemistry and biophysics.

[26]  J. Griffin,et al.  Urate crystal--dependent cleavage of Hageman factor in human plasma and synovial fluid. , 1980, The Journal of laboratory and clinical medicine.

[27]  J. Griffin,et al.  Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma , 1978, The Journal of experimental medicine.

[28]  R. Colman,et al.  Plasma kallikrein activation and inhibition during typhoid fever. , 1978, The Journal of clinical investigation.

[29]  R. Colman,et al.  Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. , 1975, The Journal of clinical investigation.

[30]  K. Austen,et al.  A PREALBUMIN ACTIVATOR OF PREKALLIKREIN , 1972, The Journal of experimental medicine.

[31]  K. Austen,et al.  A PREALBUMIN ACTIVATOR OF PREKALLIKREIN , 1971, The Journal of experimental medicine.

[32]  R. Colman,et al.  Plasma kallikrein and Hageman factor in Gram-negative bacteremia. , 1970, Annals of internal medicine.

[33]  R. R. Proctor,et al.  The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. , 1961, American journal of clinical pathology.

[34]  M. Rocha e Silva,et al.  Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. , 1949, The American journal of physiology.

[35]  K. Austen,et al.  A PREALBUMIN ACTIVATOR OF PREKALLIKREIN II . DERIVATION OF ACTIVATORS OF PREKALLIKREIN FROM ACTIVE HAGEMAN FACTOR BY DIGESTION WITtt PLASMIN , 2003 .

[36]  R. Colman,et al.  Prognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome. , 1995, Critical care medicine.

[37]  R. Colman,et al.  The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. , 1993, The Journal of clinical investigation.

[38]  R. Tidwell,et al.  Sequential events in the pathogenesis of streptococcal cell wall-induced arthritis and their modulation by bis(5-amidino-2-benzimidazolyl)methane (BABIM). , 1990, The American journal of pathology.

[39]  R. Colman,et al.  A monoclonal anti-human plasma prekallikrein antibody that inhibits activation of prekallikrein by factor XIIa on a surface. , 1987, Blood.

[40]  J F Morrison,et al.  The kinetics of reversible tight-binding inhibition. , 1979, Methods in enzymology.

[41]  J. Morrison,et al.  [17] The kinetics of reversible tight-binding inhibition , 1979 .